Wednesday, April 21, 2021 10:29:15 AM
8:10 am ET April 21, 2021 (Dow Jones) Print
By Josh Nathan-Kazis
A day after CRISPR Therapeutics said that Vertex Pharmaceuticals would pay it $900 million for an extra 10% of the profits from sales of a gene-editing therapy called CTX001, a Jefferies analyst upgraded the stock to Buy, from Hold.
CRISPR (ticker: CRSP) and Vertex (VRTX) have jointly developed CTX001, which is being tested to treat patients with sickle cell disease and beta thalassemia, under a deal first signed in 2015. Under the new agreement, the 50/50 split under the old deal will now be a 60/40 split in favor of Vertex. In addition to the $900 million up front, Vertex will pay an additional $200 million when the therapy receives regulatory approval.
In a research note published early Wednesday, Jefferies analyst Maury Raycroft wrote that the deal validated the large market opportunity for the therapy, which he said is underappreciated by analysts. What's more, he said that the CTX001 program "has turned more into execution more for registration + launch [preparation]."
Raycroft upgraded CRISPR to Buy, from Hold, and set a price target of $172, up from $165. The stock closed Tuesday at $121.67.
Shares of CRISPR climbed 5.8% on Tuesday in response to the news, and were up another 1.8% in premarket trading on Wednesday. The stock is down 20.5% so far this year, and up 132.2% over the past 12 months.
In his note, Raycroft wrote that the recent pullback in shares had created a buying opportunity for investors. The stock is down 34.3% since Jan. 20, a period in which the S&P 500 has climbed 7.4%, and the SPDR S&P Biotech ETF (XBI) is down 14.9%.
Raycroft also said that the large amount of capital that CRISPR now has in the bank could help the company accelerate its other programs.
On CTX001, Raycroft wrote that the company will present more data on the therapy in 2021, and will fully enroll both its continuing studies in sickle cell disease and beta thalassemia this year. He also said that the company told him that they had made progress on ongoing discussions with regulators about what data they will need to file for approval for the therapy.
Of the 21 analysts who cover CRISPR tracked by FactSet, 13 rate it a Buy, while six rate it a Hold and two rate it a Sell. Their average target price of $153.44 implies a return of 26.1%.
Write to editors@barrons.com
(END) Dow Jones Newswires
New York Yankees and Duke Basketball
Recent CRSP News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/12/2024 10:45:42 PM
- Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers • Edgar (US Regulatory) • 08/05/2024 09:22:43 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 08/05/2024 08:54:10 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/05/2024 08:10:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/05/2024 08:05:11 PM
- CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results • GlobeNewswire Inc. • 08/05/2024 08:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/03/2024 12:06:56 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/31/2024 08:15:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/31/2024 08:15:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/31/2024 08:15:03 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/30/2024 08:26:54 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/29/2024 08:15:03 PM
- CRISPR Therapeutics to Participate in Upcoming Investor Conferences • GlobeNewswire Inc. • 05/29/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/24/2024 08:15:54 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/23/2024 08:25:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/23/2024 12:14:37 PM
- CRISPR Therapeutics Strengthens Executive Leadership Team with Key Appointments • GlobeNewswire Inc. • 05/23/2024 12:00:00 PM
- CRISPR Therapeutics to Present at the Bank of America Securities Health Care Conference • GlobeNewswire Inc. • 05/09/2024 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/08/2024 08:20:38 PM
- CRISPR Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results • GlobeNewswire Inc. • 05/08/2024 08:00:00 PM
- CRISPR Therapeutics Highlights ASGCT Oral Presentation and Announces New Programs Utilizing In Vivo Gene Editing Approach • GlobeNewswire Inc. • 05/08/2024 11:00:00 AM
- CRISPR Therapeutics to Present Oral Presentation at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting • GlobeNewswire Inc. • 04/22/2024 08:30:00 PM
- CRISPR Therapeutics to Present at the Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/03/2024 12:00:00 PM
- CRISPR Therapeutics to Present at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting • GlobeNewswire Inc. • 04/01/2024 12:00:00 PM
- CRISPR Therapeutics Proposes New Appointment to the Board of Directors • GlobeNewswire Inc. • 03/13/2024 12:30:00 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM